Literature DB >> 19189904

Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial.

Claire Vanlemmens1, Vincent Di Martino, Chantal Milan, Michel Messner, Anne Minello, Christophe Duvoux, Thierry Poynard, Jean-Marc Perarnau, Marie-Anne Astrid Piquet, Georges-Philippe Pageaux, Sébastien Dharancy, Christine Silvain, Sophie Hillaire, Gérard Thiefin, Jean-Pierre Vinel, Patrick Hillon, Estelle Collin, Georges Mantion, Jean-Philippe Miguet.   

Abstract

BACKGROUND: Liver transplantation improves survival of patients with end-stage (Child-Pugh stage C) alcoholic cirrhosis, but its benefit for patients with stage B disease is uncertain.
OBJECTIVE: To compare the outcomes of patients with Child-Pugh stage B alcoholic cirrhosis who are immediately listed for liver transplantation with those of patients assigned to standard treatment with delay of transplantation until progression to stage C disease.
DESIGN: Randomized, controlled trial.
SETTING: 13 liver transplantation programs in France. PATIENTS: 120 patients with Child-Pugh stage B alcoholic cirrhosis and no viral hepatitis, cancer, or contraindication to transplantation.
INTERVENTIONS: Patients were randomly assigned to immediate listing for liver transplantation (60 patients) or standard care (60 patients). MEASUREMENTS: Overall and cancer-free survival over 5 years.
RESULTS: Sixty-eight percent of patients assigned to immediate listing for liver transplantation and 25% of those assigned to standard care received a liver transplant. All-cause death and cirrhosis-related death did not statistically differ between the 2 groups: 5-year survival was 58% (95% CI, 43% to 70%) for those assigned to immediate listing versus 69% (CI, 54% to 80%) for those assigned to standard care. In multivariate analysis, independent predictors of long-term survival were absence of ongoing alcohol consumption (hazard ratio, 7.604 [CI, 2.395 to 24.154]), recovery from Child-Pugh stage C (hazard ratio, 7.633 [CI, 2.392 to 24.390]), and baseline Child-Pugh score less than 8 (hazard ratio, 2.664 [CI, 1.052 to 6.746]). Immediate listing for transplantation was associated with an increased risk for extrahepatic cancer: The 5-year cancer-free survival rate was 63% (CI, 43% to 77%) for patients who were immediately listed and 94% (CI, 81% to 98%) for those who received standard care. LIMITATION: Restriction of the study sample to alcoholic patients may limit the generalizability of results to other settings.
CONCLUSION: Immediate listing for liver transplantation did not show a survival benefit compared with standard care for Child-Pugh stage B alcoholic cirrhosis. In addition, immediate listing for transplantation increased the risk for extrahepatic cancer. FUNDING: The French National Program for Clinical Research.

Entities:  

Mesh:

Year:  2009        PMID: 19189904     DOI: 10.7326/0003-4819-150-3-200902030-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  13 in total

1.  Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule?

Authors:  Julie Zhu; Trana Hussaini; Eric M Yoshida
Journal:  Ann Transl Med       Date:  2018-10

2.  A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.

Authors:  Stephan Buch; Felix Stickel; Eric Trépo; Michael Way; Alexander Herrmann; Hans Dieter Nischalke; Mario Brosch; Jonas Rosendahl; Thomas Berg; Monika Ridinger; Marcella Rietschel; Andrew McQuillin; Josef Frank; Falk Kiefer; Stefan Schreiber; Wolfgang Lieb; Michael Soyka; Nasser Semmo; Elmar Aigner; Christian Datz; Renate Schmelz; Stefan Brückner; Sebastian Zeissig; Anna-Magdalena Stephan; Norbert Wodarz; Jacques Devière; Nicolas Clumeck; Christoph Sarrazin; Frank Lammert; Thierry Gustot; Pierre Deltenre; Henry Völzke; Markus M Lerch; Julia Mayerle; Florian Eyer; Clemens Schafmayer; Sven Cichon; Markus M Nöthen; Michael Nothnagel; David Ellinghaus; Klaus Huse; Andre Franke; Steffen Zopf; Claus Hellerbrand; Christophe Moreno; Denis Franchimont; Marsha Y Morgan; Jochen Hampe
Journal:  Nat Genet       Date:  2015-10-19       Impact factor: 38.330

3.  Predictors of relapse to significant alcohol drinking after liver transplantation.

Authors:  Zamil Karim; Pongphob Intaraprasong; Charles H Scudamore; Siegfried R Erb; John G Soos; Elsie Cheung; Polly Cooper; Andrzej K Buzckowski; Stephen W Chung; Urs P Steinbrecher; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2010-04       Impact factor: 3.522

Review 4.  Alcoholic liver disease: treatment.

Authors:  Ki Tae Suk; Moon Young Kim; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Treatment of alcoholic liver disease.

Authors:  Thomas H Frazier; Abigail M Stocker; Nicole A Kershner; Luis S Marsano; Craig J McClain
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

6.  Liver transplantation for alcoholic liver disease.

Authors:  Vibha Varma; Kerry Webb; Darius F Mirza
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

7.  Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation.

Authors:  Gabriel Thabut; Jason D Christie; Hervé Mal; Michel Fournier; Olivier Brugière; Guy Leseche; Yves Castier; Dimitris Rizopoulos
Journal:  Am J Respir Crit Care Med       Date:  2013-06-15       Impact factor: 21.405

Review 8.  Alcoholic hepatitis: current challenges and future directions.

Authors:  Ashwani K Singal; Patrick S Kamath; Gregory J Gores; Vijay H Shah
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-28       Impact factor: 11.382

Review 9.  Liver transplantation for alcoholic liver disease: Lessons learned and unresolved issues.

Authors:  José Ursic-Bedoya; Stéphanie Faure; Hélène Donnadieu-Rigole; Georges-Philippe Pageaux
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  KASL clinical practice guidelines: management of alcoholic liver disease.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2013-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.